



Serac Healthcare Partners with University of Oxford to Evaluate the Potential of ^{99m}Tc-Maraciclalide to Diagnose Endometriosis Non-Invasively

7th June 2022

Serac Healthcare Ltd is working with the University of Oxford to investigate whether an experimental image marker (^{99m}Tc-maraciclalide) that binds to areas of inflammation can be used to visualise endometriosis using a 20-minute scan.

Endometriosis, a disease that affects one in 10 women of child bearing age, typically results in multiple physician and hospital visits, multiple scans and often surgery to confirm the diagnosis. As a result, there is an average delay of approximately eight years to secure a diagnosis, a figure that has not improved in the last decade. One of the main reasons for this delay is the lack of non-invasive tests capable of detecting all endometriosis subtypes (ovarian, superficial, and deep disease).

Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford said: *'There is an urgent unmet clinical need for a non-invasive marker to identify or rule out endometriosis as it is such a very common disease affecting more than 190 million women worldwide.'*

Professor Krina Zondervan, Head of Department at the Nuffield Department of Women's and Reproductive Health, University of Oxford, added: *'This study highlights that close collaborations between academics, clinicians and industry are important to combine and accelerate discovery and innovation in addressing high-priority areas in women's health such as endometriosis.'*

David Hail, CEO of Serac Healthcare said: *'We are excited about the potential of ^{99m}Tc-maraciclalide to diagnose endometriosis non-invasively and are delighted to be working with the internationally renowned team at Oxford on this important first study.'*

Maraciclalide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.

For more information about the study visit:

<https://www.wrh.ox.ac.uk/news/new-imaging-study-could-make-diagnosing-endometriosis-quicker-more-accurate-and-reduce-the-need-for-invasive-surgery>

About Serac Healthcare

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare is a wholly-owned subsidiary of Serac Life Sciences Ltd. www.serachealthcare.com